<DOC>
	<DOCNO>NCT02931201</DOCNO>
	<brief_summary>The purpose study evaluate whether semi-quantitative interpretation use liver SUVmax reference well interpret 18F-FDG PET/CT predict disease progression chemotherapy survival DLBCL .</brief_summary>
	<brief_title>Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria Prognosis Patients With Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>In study investigator develope semi-quantitative interpretation use liver SUVmax reference interpret 18F-FDG PET/CT . Positive lesion PET indicate SUVmax residue higher threshold ( 1.6 fold liver SUVmax ) new 18F-FDG avid lesion . Investigators compare prognostic accuracy liver SUVmax-based criterion 5-PS criterion Î”SUVmax interpretation respect predict disease progression chemotherapy survival DLBCL . Furthermore , investigator improve prognostic ability interim PET/CT compare result clinical prognostic factor .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>newly diagnose DLBCL treat use anthracyclinecontaining regimen without rituximab minimal followup 6 month completion firstline treatment complete medical history clinicopathological data secondary malignant disease serious infection inflammation ( e.g. , HIV ) primary central nervous system lymphoma hepatic renal dysfunction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Positron-Emission Tomography</keyword>
	<keyword>Prognosis</keyword>
</DOC>